GinsenoLife Sciences

GinsenoLife Sciences is a clinical-stage biotechnology company dedicated to the development of therapies for rare lysosomal storage diseases and neurodegenerative conditions. The company utilizes a proprietary platform to develop synthetic derivatives of ginsenosides, which are bioactive compounds found in ginseng. Its lead candidate, GLS-102, is being investigated for the treatment of Niemann-Pick Disease Type C, a fatal genetic disorder characterized by the inability of the body to transport cholesterol and other lipids. GinsenoLife's research is rooted in discoveries made at the University of Central Florida, focusing on the neuroprotective and metabolic regulatory properties of its compounds. The company aims to provide disease-modifying options for patients with high unmet medical needs.